ltraviolet related DNA-damage in skin of patients with atopic dermatitis and atopic status in relation to the use of Myfortic® - Effect of Myfortic® on UV-induced DNA-damage and atopic status

niversitair Medisch Centrum Utrecht0 个研究点目标入组 10 人开始时间: 待定最近更新: 2024年6月18日

适应症

试验速览

暂无简介。

•- age from 18 years
•- atopic dermatitis according to the criteria of Hanifin and Rajka
•- insufficient respons to topical therapy alone
•- the physician estimates that treatment with oral immunosuppressiva agents is indicated.

•- patients with any known hypersensitivity to mycofenolic acid or other components of the formulation.
•- oral immunosuppressive treatment in the last 6 weeks.
•- concomittant UV therapy or UV therapy in the last two months.
•- contact with UV on the laesional skin for the last two months.
•- patients with thrombocytopenia (<75.000/mm3), with an absolute neutrophil count <1.500/mm3 and/or leukocytopenia (<2.500/mm3) and/or hemoglobin <6,0g/dl priot to enrollment.
•- patients who have received an investigational drug within two weeks prior to screening
•- patients with a history of malignancy within the last five years.
•- Females of childbearing potential who are planning to become pregnant, who are pregnant and/or lactating, who are unwilling to use effective means of contraception.
•- Patients with an immunologic disorder (like RA, SLE or M. Sjögren) or a preexistent dermatologic disorder that worsens in combination with UV (like LE or photosensitive eczema).
•- Presence of clinically significant infection requiring continued therapy, severe diarrhea or uncontrolled diabetes mellitus that would interfere with the appropiate conduct of the study.

发起方

niversitair Medisch Centrum Utrecht